Illumina Posts Higher 4Q Profit, Revenue

Dow Jones02-06

Illumina logged higher profit and revenue in the fourth quarter, and raised its outlook for the current year.

The medical specialties company reported a fourth-quarter net income of $334 million, or $2.16 a share, compared with earnings of $187 million, or $1.17 per share, a year earlier.

Adjusted earnings came in at $1.35. Analysts polled by FactSet had forecast adjusted earnings of $1.24 a share.

Revenue grew 5% to $1.16 billion, beating the $1.12 billion expected by analysts, according to FactSet.

During the fourth quarter, Illumina said it completed its acquisition of SomaLogic, expanding the company's multiomics portfolio and strengthening its position in scalable, NGS-enabled proteomics.

For 2026, Illumina anticipates adjusted earnings of $5.05 to $5.20 a share, including 18 cents in dilution from the SomaLogic acquisition. The company expects revenue of $4.5 billion to $4.6 billion.

Analysts polled by FactSet forecast adjusted earnings of $5.06 a share on revenue of $4.41 billion in 2026.

Free cash flow from operations minus capital expenditures was $267 million in the quarter, down from $322 million in the prior year period.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609389025?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 07:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609389025","market":"other","top_or_hot":-1,"title":"Illumina Posts Higher 4Q Profit, Revenue","media":"Dow Jones","content":"<p><a href=\"https://laohu8.com/S/ILMN\">Illumina</a> logged higher profit and revenue in the fourth quarter, and raised its outlook for the current year.</p><p>The medical specialties company reported a fourth-quarter net income of $334 million, or $2.16 a share, compared with earnings of $187 million, or $1.17 per share, a year earlier.</p><p>Adjusted earnings came in at $1.35. Analysts polled by FactSet had forecast adjusted earnings of $1.24 a share.</p><p>Revenue grew 5% to $1.16 billion, beating the $1.12 billion expected by analysts, according to FactSet.</p><p>During the fourth quarter, Illumina said it completed its acquisition of SomaLogic, expanding the company's multiomics portfolio and strengthening its position in scalable, NGS-enabled proteomics.</p><p>For 2026, Illumina anticipates adjusted earnings of $5.05 to $5.20 a share, including 18 cents in dilution from the SomaLogic acquisition. The company expects revenue of $4.5 billion to $4.6 billion.</p><p>Analysts polled by FactSet forecast adjusted earnings of $5.06 a share on revenue of $4.41 billion in 2026.</p><p>Free cash flow from operations minus capital expenditures was $267 million in the quarter, down from $322 million in the prior year period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina Posts Higher 4Q Profit, Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina Posts Higher 4Q Profit, Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-06 07:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><a href=\"https://laohu8.com/S/ILMN\">Illumina</a> logged higher profit and revenue in the fourth quarter, and raised its outlook for the current year.</p><p>The medical specialties company reported a fourth-quarter net income of $334 million, or $2.16 a share, compared with earnings of $187 million, or $1.17 per share, a year earlier.</p><p>Adjusted earnings came in at $1.35. Analysts polled by FactSet had forecast adjusted earnings of $1.24 a share.</p><p>Revenue grew 5% to $1.16 billion, beating the $1.12 billion expected by analysts, according to FactSet.</p><p>During the fourth quarter, Illumina said it completed its acquisition of SomaLogic, expanding the company's multiomics portfolio and strengthening its position in scalable, NGS-enabled proteomics.</p><p>For 2026, Illumina anticipates adjusted earnings of $5.05 to $5.20 a share, including 18 cents in dilution from the SomaLogic acquisition. The company expects revenue of $4.5 billion to $4.6 billion.</p><p>Analysts polled by FactSet forecast adjusted earnings of $5.06 a share on revenue of $4.41 billion in 2026.</p><p>Free cash flow from operations minus capital expenditures was $267 million in the quarter, down from $322 million in the prior year period.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILMN","symbol_name":"Illumina","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2609389025","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609389025","pubTimestamp":1770335481,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Illumina logged higher profit and revenue in the fourth quarter, and raised its outlook for the current year.The medical specialties company reported a fourth-quarter net income of $334 million, or $2.16 a share, compared with earnings of $187 million, or $1.17 per share, a year earlier.Adjusted earnings came in at $1.35. Analysts polled by FactSet had forecast adjusted earnings of $1.24 a share.Revenue grew 5% to $1.16  billion, beating the $1.12 billion expected by analysts, according to FactSet.During the fourth quarter, Illumina said it completed its acquisition of SomaLogic, expanding the company's multiomics portfolio and strengthening its position in scalable, NGS-enabled proteomics.For 2026, Illumina anticipates adjusted earnings of $5.05 to $5.20 a share, including 18 cents in dilution from the SomaLogic acquisition. The company expects revenue of $4.5 billion to $4.6 billion.Analysts polled by FactSet forecast adjusted earnings of $5.06 a share on revenue of $4.41 billion in ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ILMN":"Illumina"},"translate_title":"Illumina第四季度利润和收入较高","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1.5},"content_text":"Illumina logged higher profit and revenue in the fourth quarter, and raised its outlook for the current year.The medical specialties company reported a fourth-quarter net income of $334 million, or $2.16 a share, compared with earnings of $187 million, or $1.17 per share, a year earlier.Adjusted earnings came in at $1.35. Analysts polled by FactSet had forecast adjusted earnings of $1.24 a share.Revenue grew 5% to $1.16 billion, beating the $1.12 billion expected by analysts, according to FactSet.During the fourth quarter, Illumina said it completed its acquisition of SomaLogic, expanding the company's multiomics portfolio and strengthening its position in scalable, NGS-enabled proteomics.For 2026, Illumina anticipates adjusted earnings of $5.05 to $5.20 a share, including 18 cents in dilution from the SomaLogic acquisition. The company expects revenue of $4.5 billion to $4.6 billion.Analysts polled by FactSet forecast adjusted earnings of $5.06 a share on revenue of $4.41 billion in 2026.Free cash flow from operations minus capital expenditures was $267 million in the quarter, down from $322 million in the prior year period.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609389025","isCrawlerRequest":true}